BGPT: Paper Review: Reactive oxygen species (ROS): Critical roles in breast tumor microenvironment

Explore by Goal

Quick Explanation Copied

Paper focus (what it claims)

ROS are presented as context-dependent signaling molecules that remodel the breast tumor microenvironment (TME)—driving ECM/cancer-associated fibroblasts, endothelial and immune reprogramming, metabolic/epigenetic changes, metastasis, and drug resistance—while also creating a therapeutic “conundrum” due to pro- vs anti-tumor effects depending on ROS levels and context.

Anchor

Long Explanation

Reactive oxygen species (ROS): Critical roles in breast tumor microenvironment — Critical visual review

Paper: 10.1016/j.critrevonc.2021.103285 • Published: 11 March 2021 • Type: narrative review (as provided text indicates “presents a detailed and comprehensive review”)

1) Visual synthesis (ROS → TME remodeling → outcomes)

Cited basis

The review explicitly connects ROS to multiple TME remodeling processes and downstream outcomes (metastasis and drug resistance), and highlights a dual functional role dependent on context/levels.

2) What the review actually says (scope map by section)

Skeptical note

This “coverage” chart is not a quantitative citation-count analysis; it is only a visual guide to where the provided full text spends most of its framing (from your pasted content). Any numeric meaning beyond “more vs less” is not claimed.

3) The “therapeutic conundrum” the review emphasizes

Cited basis

The review explicitly states ROS have dual roles (proliferation vs apoptosis) and discusses a “therapeutic conundrum” for ROS-modulating strategies, arguing context/ROS level matters and monotherapies may fail in drug-resistant settings.

4) Mechanistic plausibility & skeptical critique (review-level)

Strength: breadth of mechanistic coupling (ROS ↔ metabolism ↔ epigenetics ↔ TME components). The review repeatedly links ROS to multiple “reprogramming” layers (ECM/CAFs/endothelium/immune + metabolic + genetic/epigenetic + signaling) and then to metastasis and resistance, aligning with the idea of ROS as a multi-target redox signal.
Blind spot: causal granularity. Because this is a narrative review (per provided excerpt) rather than a synthesis with explicit inclusion criteria, the mechanistic narrative may underrepresent contradictory evidence or uncertainty about the directionality of ROS changes (cause vs consequence) for each TME component.
Translation risk: ROS measurement and species/model dependence. The review discusses ROS as a therapeutic target, but redox biology is notoriously sensitive to measurement modality and experimental context; without systematic triangulation, ROS “level” categories (physiological vs high) can be model- and assay-dependent. The review itself flags context dependence and a conundrum, which partially acknowledges this risk.
Potential overreach: phytochemicals vs ROS mechanism specificity. The review lists ROS-mediated activity of multiple phytochemicals and clinically approved drugs, but the excerpt does not provide assay harmonization (same cell types, ROS probes, doses, ROS species) or causal dissection that would be needed to compare “ROS-mediated” across compounds reliably. This is a structural limitation of the review format, not necessarily an error in the underlying studies.

What would disprove the review’s central premise?

If rigorous in vivo/clinical evidence showed that ROS modulation in the breast TME does not measurably affect metastasis, drug resistance, or immune suppression across multiple subtypes/models—or that ROS-targeting harms outcomes via compensatory antioxidant pathways beyond what the “conundrum” predicts—then the review’s ROS-centric causal framework would be weakened. The review’s own “conundrum” framing implies that directionality is not simple and would require such tests.

5) Visualizing the review’s main figure claims (from provided figures)

Figure 1: ROS functions at physiological levels promoting survival (EMT/stemness/metabolic shift) but at higher levels with therapy inducing apoptosis.
Figure 2: ROS promotes TME reprogramming via increasing HIF-1α and glycolytic transcription, which enhances hypoxia and acidity, and suppresses antitumor immunity.

Author-declared conflicts (from provided text)

The review states: “The authors report no declarations of interest.”

Explore authors on BGPT

Feedback:

Updated: March 20, 2026